ArticleCurrent hepatology reports2020
Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy.
Article in Current hepatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Efficacy and safety of TDF+3TC + EFV‑centric antiretroviral regimens for HIV/HBV co-infection: a systematic review and network meta‑analysis.BMC infectious diseases · 2026Pooled it
- HBV Serological Profiles and Vaccination Status in People with HIV in the Transition to a Tenofovir-Sparing Era: Insights from a Large HIV Cohort.Infectious diseases and therapy · 2026Article
- Prevalence and determinants of hepatitis B, hepatitis C, and liver injury among people living with HIV on antiretroviral therapy in the Upper East Region of Ghana.BMC infectious diseases · 2026Article
- Immunological research landscapes and emerging immune mechanisms in HIV/HBV co-infection: a bibliometric analysis (2014-2024).Frontiers in immunology · 2026Review
- Prevalence, associated factors, and viral load dynamics of hepatitis B virus infection among HIV patients in three healthcare facilities of South Kivu province, eastern Democratic Republic of Congo : Chronic hepatitis B virus among HIV patients in South Kivu province.BMC infectious diseases · 2025Article
- Research on Perinatal Human Immunodeficiency Virus in Asia: Data on Treatment Outcomes and Emerging Co-Morbidities from the TREAT Asia Network.Clinics in perinatology · 2024Review
- Prevalence of occult hepatitis B infection among treatment-naive persons living with HIV in Ghana.PloS one · 2024Article
- Persistent hepatitis B virus and HIV coinfections in dually humanized mice engrafted with human liver and immune system.Journal of medical virology · 2023Article
- Review
- Analysis of HIV quasispecies and virological outcome of an HIV D+/R+ kidney-liver transplantation.Virology journal · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe burden of chronic hepatitis B (HBV) remains disproportionately high among people living with HIV (PLWH) despite the advent of HBV vaccination and HBV-active antiretroviral therapy (ART). This review summarizes new insights and evolving issues in HIV-HBV coinfection. RECENT
findingsHBV-HIV coinfection is still a leading cause of cirrhosis, hepatocellular carcinoma (HCC) and liver-related mortality more than a decade after the approval of tenofovir. While tenofovir-based ART has been shown to improve rates of HBV virologic suppression and halt fibrosis progression, the long-term benefits on the prevention of end-stage liver disease or HCC in HIV-HBV coinfection have yet to be convincingly demonstrated in PLWH. Missed opportunities for HBV vaccination persist despite evidence of ongoing risk for HBV infection in this population. SUMMARY: Even as we work towards HBV elimination and functional cure, ongoing efforts should focus on optimizing risk stratification as well as uptake of HBV-active antiviral therapy and HBV immunization in this priority population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.